Tessera Therapeutics shared a post on LinkedIn:
“Today we announced preclinical data presented at the 66th American Society of Hematology (ASH) Annual Meeting, highlighting advances in our in vivo therapies for sickle cell disease (SCD) and T cell therapies. Read more here.”
More posts featuring ASH24.